Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Necessary Expansion of the Management Board at Rentschler Biotechnologie

Published: Thursday, November 08, 2012
Last Updated: Wednesday, November 07, 2012
Bookmark and Share
Frank Ternes to become Managing Director of Sales at Rentschler.

The family-owned business based in Laupheim has expanded its management board. As a contract manufacturing organization, Rentschler Biotechnologie GmbH performs research on, develops, and produces biologicals for its international clientele.

Reiner Winkelbauer, who has been the company's Commercial Manager for the past four years, was appointed Managing Director of Finances.

He was previously the Controlling and Chief Financial Officer of AEG in Ulm and later became the Commercial Manager at EADS also in Ulm.

Since September 1, 2012, Thomas Siklosi has strengthened the management board in the GMP Operations area. Before he started working at Rentschler Biotechnologie as manager of the Active Substance Department in 1984, Siklosi worked for Boehringer Mannheim for 10 years. In 2008, he took over the management of GMP Operations at Rentschler.

In the future, Siklosi will also be responsible for the "operational excellence" program at Rentschler that will focus on customer needs and on optimizing quality and efficiency.

Starting from November 1, 2012, he will be actively supported by Luca Dellacroce, the "new face" in Rentschler's management board. In the past, Dellacroce worked for notable companies such as Motorola and Nokia in process optimization.

Frank Ternes will also be a new addition to the management level at Rentschler beginning February 1, 2013.

After 25 years at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing, Ternes will now become Managing Director of Sales at Rentschler.

Dr. Nikolaus F. Rentschler, CEO and owner, explains the necessary changes that led to a larger management board as follows:

"To accommodate the rapid growth of the company during the past 10 years, the management board had to also "grow." Internal processes must be constantly reconsidered and optimized in order to serve our customers even better and more efficiently. For this reason, I decided to implement the necessary steps to achieve process optimization in my company. I wish Messrs. Winkelbauer, Siklosi, Dellacroce, and Ternes the strength and fortitude, as well as the determination and perseverance to act in the interests and for the success of my company."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos